800 related articles for article (PubMed ID: 25988241)
1. Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative.
Mackey RH; Kuller LH; Deane KD; Walitt BT; Chang YF; Holers VM; Robinson WH; Tracy RP; Hlatky MA; Eaton CB; Liu S; Freiberg MS; Talabi MB; Schelbert EB; Moreland LW
Arthritis Rheumatol; 2015 Sep; 67(9):2311-22. PubMed ID: 25988241
[TBL] [Abstract][Full Text] [Related]
2. Determinants of mortality among postmenopausal women in the women's health initiative who report rheumatoid arthritis.
Kuller LH; Mackey RH; Walitt BT; Deane KD; Holers VM; Robinson WH; Sokolove J; Chang Y; Liu S; Parks CG; Wright NC; Moreland LW
Arthritis Rheumatol; 2014 Mar; 66(3):497-507. PubMed ID: 24574208
[TBL] [Abstract][Full Text] [Related]
3. Human Leukocyte Antigen Shared Epitope and Inflammation, Cardiovascular Disease, Cancer, and Mortality Among Postmenopausal Women in the Women's Health Initiative Rheumatoid Arthritis Study.
Birru Talabi M; Mackey RH; Kuller LH; Dorman JS; Deane KD; Robinson WH; Walitt BT; Chang Y; Holers VM; Liu S; Moreland LW
Am J Epidemiol; 2017 Jul; 186(2):245-254. PubMed ID: 28459968
[TBL] [Abstract][Full Text] [Related]
4. Rheumatoid arthritis in the Women's Health Initiative: methods and baseline evaluation.
Kuller LH; Mackey RH; Walitt BT; Deane KD; Holers VM; Robinson WH; Sokolove J; Chang Y; Moreland LW
Am J Epidemiol; 2014 Apr; 179(7):917-26. PubMed ID: 24569640
[TBL] [Abstract][Full Text] [Related]
5. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
6. Anticyclic Citrullinated Peptide Antibodies and Rheumatoid Factor as Risk Factors for 10-year Cardiovascular Morbidity in Patients with Rheumatoid Arthritis: A Large Inception Cohort Study.
Berendsen MLT; van Maaren MC; Arts EEA; den Broeder AA; Popa CD; Fransen J
J Rheumatol; 2017 Sep; 44(9):1325-1330. PubMed ID: 28668802
[TBL] [Abstract][Full Text] [Related]
7. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.
Bruns A; Nicaise-Roland P; Hayem G; Palazzo E; Dieudé P; Grootenboer-Mignot S; Chollet-Martin S; Meyer O
Joint Bone Spine; 2009 May; 76(3):248-53. PubMed ID: 19208451
[TBL] [Abstract][Full Text] [Related]
8. Interactions between smoking, increased serum levels of anti-CCP antibodies, rheumatoid factors, and erosive joint disease in patients with early, untreated rheumatoid arthritis.
Krol A; Garred P; Heegaard NH; Christensen AF; Hetland ML; Stengaard-Pedersen K; Junker P; Madsen HO; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Pedersen JK; Svendsen AJ; Tarp U; Pødenphant J; Lindegaard H; Østergaard M; Hørslev-Petersen K; Jacobsen S
Scand J Rheumatol; 2015; 44(1):8-12. PubMed ID: 25205362
[TBL] [Abstract][Full Text] [Related]
9. Enhanced neutrophil phagocytic capacity in rheumatoid arthritis related to the autoantibodies rheumatoid factor and anti-cyclic citrullinated peptides.
de Siqueira MB; da Mota LM; Couto SC; Muniz-Junqueira MI
BMC Musculoskelet Disord; 2015 Jun; 16():159. PubMed ID: 26123215
[TBL] [Abstract][Full Text] [Related]
10. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
[TBL] [Abstract][Full Text] [Related]
11. Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anti-cyclic citrullinated peptide antibody status.
Bang SY; Lee KH; Cho SK; Lee HS; Lee KW; Bae SC
Arthritis Rheum; 2010 Feb; 62(2):369-77. PubMed ID: 20112396
[TBL] [Abstract][Full Text] [Related]
12. Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis.
Caspi D; Anouk M; Golan I; Paran D; Kaufman I; Wigler I; Levartovsky D; Litinsky I; Elkayam O
Arthritis Rheum; 2006 Feb; 55(1):53-6. PubMed ID: 16463412
[TBL] [Abstract][Full Text] [Related]
13. Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review.
Barra L; Pope J; Bessette L; Haraoui B; Bykerk V
Rheumatology (Oxford); 2011 Feb; 50(2):311-6. PubMed ID: 20621983
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to Cyclic Citrullinated Peptides in Patients With Juvenile Idiopathic Arthritis and Patients With Rheumatoid Arthritis: Shared Expression of the Inherently Autoreactive 9G4 Idiotype.
Peckham H; Cambridge G; Bourke L; Sen D; Radziszewska A; Leandro M; Ioannou Y
Arthritis Rheumatol; 2017 Jul; 69(7):1387-1395. PubMed ID: 28380667
[TBL] [Abstract][Full Text] [Related]
15. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody.
Mikuls TR; O'Dell JR; Stoner JA; Parrish LA; Arend WP; Norris JM; Holers VM
Arthritis Rheum; 2004 Dec; 50(12):3776-82. PubMed ID: 15593224
[TBL] [Abstract][Full Text] [Related]
16. Anti-CCP and RF IgM: predictors of impaired endothelial function in rheumatoid arthritis patients.
Hjeltnes G; Hollan I; Førre Ø; Wiik A; Mikkelsen K; Agewall S
Scand J Rheumatol; 2011 Nov; 40(6):422-7. PubMed ID: 22150462
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of anti cyclic citrullinated peptide antibodies in Malaysian rheumatoid arthritis patients and its correlation with disease activity.
Sockalingam S; Khuan CS; Sthaneshwar P
Int J Rheum Dis; 2009 Sep; 12(3):211-5. PubMed ID: 20374348
[TBL] [Abstract][Full Text] [Related]
18. Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study.
Ajeganova S; Andersson ML; Frostegård J; Hafström I
J Rheumatol; 2013 Dec; 40(12):1958-66. PubMed ID: 23950188
[TBL] [Abstract][Full Text] [Related]
19. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment.
Caramaschi P; Biasi D; Tonolli E; Pieropan S; Martinelli N; Carletto A; Volpe A; Bambara LM
Rheumatol Int; 2005 Nov; 26(1):58-62. PubMed ID: 15726373
[TBL] [Abstract][Full Text] [Related]
20. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis.
van der Helm-van Mil AH; Verpoort KN; Breedveld FC; Toes RE; Huizinga TW
Arthritis Res Ther; 2005; 7(5):R949-58. PubMed ID: 16207336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
